サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566964

アトルバスタチンカルシウム市場：形態別、用途別、流通チャネル別：世界の機会分析と産業予測、2024～2033年

Atorvastatin Calcium Market By Form , By Application By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
アトルバスタチンカルシウム市場：形態別、用途別、流通チャネル別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アトルバスタチンカルシウム市場は、2023年に2億9,830万米ドルと評価され、2024～2033年にかけてCAGR 5％で成長し、2033年には4億8,780万米ドルに達すると予測されています。

アトルバスタチンカルシウムはスタチン系薬剤で、心血管疾患予防の第一選択薬として作用します。肝臓でのコレステロール合成に重要な役割を果たす酵素HMG-CoA還元酵素を阻害することにより、血中のコレステロール値を低下させる。この薬は低比重リポ蛋白（LDL）コレステロールを下げるのに効果的で、高比重リポ蛋白（HDL）コレステロールを上げるのにも役立ちます。コレステロール値を管理することにより、アトルバスタチンカルシウムは心臓発作、脳卒中、その他の重篤な心血管イベントの予防に重要な役割を果たしています。

世界のアトルバスタチンカルシウム市場の成長は、心血管疾患の憂慮すべき有病率の増加が主要要因です。世界心臓連盟によると、心血管疾患は他のどの原因よりも世界の死亡原因の第一位です。2021年には世界中で約2,050万人の死亡が報告されています。さらに、高齢者人口の急増も市場成長に大きく寄与しています。これは、高齢者は高コレステロール血症や関連する心血管疾患に罹患しやすいという事実に起因しており、その結果、アトルバスタチンのようなコレステロール低下薬の需要が高まり、市場成長を後押ししています。AHA 2019 Heart Disease and Stroke Statistical Updateによると、60～79歳の心血管疾患の発症率は男性で77.2％、女性で78.2％と報告されています。さらに、座りがちなライフスタイルや不健康な食事パターンの増加は、人口のコレステロール値の上昇につながっており、それによってアトルバスタチンカルシウムの必要性が高まっています。さらに、全体的な健康のためにコレステロール値を管理することの重要性に対する一般市民の意識の高まりと、アトルバスタチンカルシウムのジェネリック医薬品が入手可能であることが、世界市場の成長を後押ししています。併用療法の人気の高まりは、市場の成長を増大させると予想される主要な動向です。例えば、アトルバスタチンカルシウムとエゼチミブのような他の薬剤との併用は、コレステロール値管理の治療効果を高めるために一般的になりつつあります。しかし、筋肉痛、肝障害、他の薬剤との相互作用など、アトルバスタチンカルシウムの潜在的な副作用に関する懸念の高まりは、その使用を制限する可能性があり、市場成長の妨げとなっています。さらに、代替スタチンや他のコレステロール低下薬が入手可能であることも、世界市場の主要な阻害要因となっています。それとは反対に、製剤とドラッグデリバリー・システムの革新は、アトルバスタチンカルシウムの有効性と利便性を高めており、予測期間中の市場成長に有利な機会を提供すると期待されています。

世界のアトルバスタチンカルシウム市場は、形態、用途、流通チャンネル、地域に区分されます。形態別では、市場は錠剤とその他に分類されます。用途別では、高コレステロール血症、高脂血症、その他に分けられます。流通チャンネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。

主要調査結果

形態別では、2023年は錠剤が市場を席巻し、2024～2033年までは錠剤が市場を席巻すると予測されます。

用途別では、高コレステロール血症が今後数年間、世界のアトルバスタチンカルシウム市場で有利なセグメントになると予測されます。

流通チャンネル別では、オンライン薬局が2033年までに主要セグメントに浮上すると予測されます。

地域別では、北米が2023年に収益面で最大の市場シェアを占め、予測期間中アトルバスタチンカルシウム市場を独占すると予測されます。

本レポートで可能なカスタマイズ（追加費用とスケジュールがあります。）

  • 国、地域、世界レベルでの患者/疫学データ
  • 顧客の関心に応じた企業プロファイルの追加
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • SWOT分析

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 アトルバスタチンカルシウム市場：形態別

  • 市場概要
  • 錠剤
  • その他

第5章 アトラスチンカルシウム市場：用途別

  • 市場概要
  • 高コレステロール血症
  • 高脂血症
  • その他

第6章 アトラスタチンカルシウム市場：流通チャンネル別

  • 市場概要
  • 病院薬局
  • ドラッグストア
  • オンラインプロバイダー

第7章 アトラスタチンカルシウム市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国のアトルバスタチンカルシウム市場
    • カナダのアトルバスタチンカルシウム市場
    • メキシコのアトルバスタチンカルシウム市場
  • 欧州
    • 主要市場動向と機会
    • フランスのアトルバスタチンカルシウム市場
    • ドイツのアトルバスタチンカルシウム市場
    • イタリアのアトルバスタチンカルシウム市場
    • スペインのアトルバスタチンカルシウム市場
    • 英国のアトルバスタチンカルシウム市場
    • その他の欧州アトルバスタチンカルシウム市場
  • アジア太平洋
    • 主要市場動向と機会
    • 中国のアトルバスタチンカルシウム市場
    • 日本のアトルバスタチンカルシウム市場
    • インドのアトルバスタチンカルシウム市場
    • 韓国のアトルバスタチンカルシウム市場
    • オーストラリアのアトルバスタチンカルシウム市場
    • その他のアジア太平洋のアトルバスタチンカルシウム市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルのアトルバスタチンカルシウム市場
    • 南アフリカのアトルバスタチンカルシウム市場
    • サウジアラビアのアトルバスタチンカルシウム市場
    • その他のラテンアメリカ・中東・アフリカのアトルバスタチンカルシウム市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第9章 企業プロファイル

  • Mylan Pharmaceuticals Inc.
  • Novartis AG
  • GlaxoSmithKline Plc
  • Amgen Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Industries Ltd
  • Merck And Co. Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca Plc
  • Pfizer Inc.
目次
Product Code: A324370

The atorvastatin calcium market was valued at $298.3 million in 2023, and is projected to reach $487.8 million by 2033, growing at a CAGR of 5% from 2024 to 2033.

Atorvastatin calcium is a statin medication, which acts as the first line of treatment for the prevention of cardiovascular diseases. It lowers the cholesterol levels in the blood by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver. This medication is effective in lowering low-density lipoprotein (LDL) cholesterol, and can also help to raise high-density lipoprotein (HDL) cholesterol. By managing cholesterol levels, atorvastatin calcium plays a crucial role in preventing heart attacks, strokes, and other serious cardiovascular events.

The growth of the global atorvastatin calcium market is majorly driven by alarming increase in prevalence of cardiovascular diseases. According to the World Heart Federation, cardiovascular diseases are the leading cause of death worldwide as compared to any other cause. Approximately 20.5 million deaths were reported in 2021 across the globe. In addition, surge in geriatric population significantly contributes toward the market growth. This is attributed to the fact that aged individuals are highly susceptible to hypercholesterolemia and related cardiovascular conditions, which, in turn, leads to higher demand for cholesterol-lowering medications like atorvastatin, thereby boosting the market growth. As per AHA 2019 Heart Disease and Stroke Statistical Update, the incidence of cardiovascular diseases was reported to be 77.2% in males and 78.2% in females, from ages 60-79 years. Moreover, rise in sedentary lifestyles and unhealthy eating patterns are leading to higher cholesterol levels among the population, thereby increasing the need for atorvastatin calcium. Furthermore, rise in public awareness of the importance of managing cholesterol levels for overall health and availability of generic versions of atorvastatin calcium boost the growth of the global market. Increase in popularity of combination therapies acts a key trend that is expected to augment the market growth. For instance, the use of atorvastatin calcium in combination with other drugs, such as ezetimibe, is becoming more common to enhance therapeutic outcomes for managing cholesterol levels. However, rise in concerns about potential side effects of atorvastatin calcium such as muscle pain, liver damage, and interactions with other medications can limit its use, which hampers the market growth. In addition, availability of alternative statins and other cholesterol-lowering drugs acts as key deterrent factor of the global market. On the contrary, innovations in drug formulation and delivery systems are enhancing the efficacy and convenience of atorvastatin calcium, which are expected to offer lucrative opportunities for the market growth during the forecast period.

The global atorvastatin calcium market is segmented into form, application, distribution channel, and region. On the basis of form, the market is categorized into tablets and others. By application, it is divided into hypercholesterolemia, hyperlipidemia, and others. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of form, the tablets segment dominated the market in 2023, and is is expected to dominate from 2024 to 2033.

By application, hypercholesterolemia is anticipated to be the lucrative segment in the global atorvastatin calcium market in the coming years.

Depending on distribution channel, online pharmacies is projected to emerge as the leading segment by 2033.

Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the atorvastatin calcium market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global atorvastatin calcium market include Mylan Pharmaceuticals Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd, Merck and Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Form

  • Tablets
  • Others

By Application

  • Hypercholesterolemia
  • Hyperlipidemia
  • Others

By Distribution Channel

  • Hospital pharmacies
  • Drug store retail pharmacies
  • Online providers.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Mylan Pharmaceuticals Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • Amgen Inc.
    • Sanofi SA
    • Teva Pharmaceuticals Industries Ltd
    • Merck and Co. Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca Plc
    • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ATORVASTATIN CALCIUM MARKET, BY FORM

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Form
  • 4.2. Tablets
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Others
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: ATORVASTATIN CALCIUM MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Hypercholesterolemia
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Hyperlipidemia
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Others
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Drug Store Retail Pharmacies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Providers.
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: ATORVASTATIN CALCIUM MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Form
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Atorvastatin Calcium Market
      • 7.2.6.1. Market Size and Forecast, By Form
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Atorvastatin Calcium Market
      • 7.2.7.1. Market Size and Forecast, By Form
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Atorvastatin Calcium Market
      • 7.2.8.1. Market Size and Forecast, By Form
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Form
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Atorvastatin Calcium Market
      • 7.3.6.1. Market Size and Forecast, By Form
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Atorvastatin Calcium Market
      • 7.3.7.1. Market Size and Forecast, By Form
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Atorvastatin Calcium Market
      • 7.3.8.1. Market Size and Forecast, By Form
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Atorvastatin Calcium Market
      • 7.3.9.1. Market Size and Forecast, By Form
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Atorvastatin Calcium Market
      • 7.3.10.1. Market Size and Forecast, By Form
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Atorvastatin Calcium Market
      • 7.3.11.1. Market Size and Forecast, By Form
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Form
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Atorvastatin Calcium Market
      • 7.4.6.1. Market Size and Forecast, By Form
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Atorvastatin Calcium Market
      • 7.4.7.1. Market Size and Forecast, By Form
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Atorvastatin Calcium Market
      • 7.4.8.1. Market Size and Forecast, By Form
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Atorvastatin Calcium Market
      • 7.4.9.1. Market Size and Forecast, By Form
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Atorvastatin Calcium Market
      • 7.4.10.1. Market Size and Forecast, By Form
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Atorvastatin Calcium Market
      • 7.4.11.1. Market Size and Forecast, By Form
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Form
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Atorvastatin Calcium Market
      • 7.5.6.1. Market Size and Forecast, By Form
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Atorvastatin Calcium Market
      • 7.5.7.1. Market Size and Forecast, By Form
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Atorvastatin Calcium Market
      • 7.5.8.1. Market Size and Forecast, By Form
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Atorvastatin Calcium Market
      • 7.5.9.1. Market Size and Forecast, By Form
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Mylan Pharmaceuticals Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Novartis AG
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. GlaxoSmithKline Plc
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Amgen Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Sanofi SA
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Teva Pharmaceuticals Industries Ltd
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Merck And Co. Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Bristol-Myers Squibb Company
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. AstraZeneca Plc
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Pfizer Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments